FDA Approves Novel Non-Stimulant Treatment for ADHD
BioSpace
APRIL 4, 2021
Shares of Supernus Pharmaceuticals were climbing in premarket trading this morning after Friday’s announcement the U.S. FDA approved the company’s non-stimulant treatment for ADHD in pediatric patients 6 to 17 years of age
Let's personalize your content